Neurology

Case Study: Use of Disease-Modifying Therapy in Elderly Patients With Multiple Sclerosis

December 01, 2022

Article

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

COVID-19 Found to Elevate Risk of Seizures More Than Influenza

December 01, 2022

Article

Individuals who had COVID-19 were 55% more likely to develop epilepsy or seizures over the following 6 months than those who had influenza.

Study Highlights Changes to the Brain Caused by Migraines

November 29, 2022

Article

Research into how perivascular spaces contribute to migraine could help better understand the complexities of how these headaches occur.

Dental Health Plays Vital Role in Cardiovascular Well-Being

November 21, 2022

Article

Research also focuses on connection between oral hygiene and other chronic diseases, neurological disorders, pulmonary infections.

FDA Accepts New Drug Application for Zilucoplan for Generalized Myasthenia Gravis

November 14, 2022

Article

Zilucoplan is a subcutaneous, self-administered peptide inhibitor of complement component 5.

Clinical Overview: Skysona for Early Cerebral Adrenoleukodystrophy

November 10, 2022

Article

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

Pharmacists Can Offer Guidance on Medication Overuse for Patients With Headache Disorders, Migraines

November 07, 2022

Article

A session presenter at the ASCP 2022 Annual Meeting explained how patients’ mismanagement of medications for headaches can lead to rebound headaches.

Lecanemab Shows Highly Statistically Significant Reduction of Clinical Decline in Early Alzheimer Disease

November 03, 2022

Article

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Patients with Multiple Sclerosis Administered Ozanimod Still Mount Response Against COVID-19 After Vaccination

October 27, 2022

Article

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

Supplementation With Lower Oxygen May Not Worsen Mortality Risk In Patients With Hypoxic-Ischemic Brain Injury

October 25, 2022

Article

In patients with hypoxic-ischemic brain injury, researchers observed no significant difference between liberal and restrictive oxygenation on any-cause death.